| Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (NCT01700673) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-06-01 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01664897) | M.D. Anderson Cancer Center | 2013-05-16 |
| INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant (NCT01602211) | Fred Hutchinson Cancer Center | 2013-05-14 |
| Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01804101) | Fred Hutchinson Cancer Center | 2013-05-07 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome (NCT02042482) | Kaplan Medical Center | 2013-05-01 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) (NCT01566695) | Celgene | 2013-04-26 |
| Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS (NCT02190695) | Fox Chase Cancer Center | 2013-04-01 |
| Human Placental-Derived Stem Cell Transplantation (NCT01586455) | New York Medical College | 2013-04-01 |
| A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome (NCT02013102) | Cttq | 2013-03-01 |
| Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes (NCT01593670) | Masonic Cancer Center, University of Minnesota | 2013-03-01 |
| Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (NCT01748240) | Groupe Francophone des Myelodysplasies | 2013-03-01 |
| Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor (NCT01794299) | Kiadis Pharma | 2013-03-01 |
| Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) (NCT02014051) | SymBio Pharmaceuticals | 2013-03-01 |
| Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (NCT01819558) | Institut Paoli-Calmettes | 2013-03-01 |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (NCT01597219) | University College, London | 2013-03-01 |
| Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients (NCT01828619) | Peking University People's Hospital | 2013-02-01 |
| GVAX vs. Placebo for MDS/AML After Allo HSCT (NCT01773395) | Dana-Farber Cancer Institute | 2013-01-08 |
| Busulfan and Cyclophosphamide Followed By ALLO BMT (NCT01685411) | Masonic Cancer Center, University of Minnesota | 2013-01-01 |
| Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT01795924) | Biosuccess Biotech Co., Ltd. | 2013-01-01 |
| APG101 in Myelodysplastic Syndrome (NCT01736436) | Apogenix GmbH | 2013-01-01 |
| Spanish Registry of Erythropoietic Stimulating Agents Study (NCT01739452) | Grupo Español de Síndromes Mielodisplásicos | 2013-01-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) (NCT02085798) | Celgene | 2012-12-17 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (NCT01690520) | Nohla Therapeutics, Inc. | 2012-12-11 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (NCT01749111) | Hospital Israelita Albert Einstein | 2012-12-01 |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (NCT01746849) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies (NCT01745913) | Weill Medical College of Cornell University | 2012-10-26 |
| Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies (NCT01682226) | Memorial Sloan Kettering Cancer Center | 2012-09-05 |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (NCT01684150) | Epizyme, Inc. | 2012-09-01 |
| Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT01433965) | University of California, Davis | 2012-08-08 |
| Total Marrow Irradiation for Refractory Acute Leukemia (NCT00686556) | Masonic Cancer Center, University of Minnesota | 2012-08-01 |
| Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome (NCT01673308) | Ulsan University Hospital | 2012-08-01 |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome (NCT01624805) | M.D. Anderson Cancer Center | 2012-06-25 |
| Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot (NCT01615146) | Ottawa Hospital Research Institute | 2012-06-01 |
| Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) (NCT01700335) | SymBio Pharmaceuticals | 2012-06-01 |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor (NCT01598025) | Memorial Sloan Kettering Cancer Center | 2012-05-02 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies (NCT01643603) | Barbara Ann Karmanos Cancer Institute | 2012-05-01 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (NCT01584531) | Traws Pharma, Inc. | 2012-05-01 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells (NCT01624701) | Singapore General Hospital | 2012-03-01 |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976) | National Cancer Institute (NCI) | 2012-03-01 |
| The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). (NCT01556477) | Nordic MDS Group | 2012-03-01 |
| 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome (NCT01652781) | Seoul St. Mary's Hospital | 2012-03-01 |
| TevaGastrim for Stem Cell Mobilization Sibling Donors (NCT01542944) | Sheba Medical Center | 2012-02-01 |
| SCT Plus Immune Therapy in Average Risk AML/MDS (NCT02117297) | New York Medical College | 2012-01-12 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors (NCT01509300) | Asan Medical Center | 2012-01-01 |
| ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS (NCT01709396) | Ottawa Hospital Research Institute | 2012-01-01 |
| Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome (NCT02060409) | Samsung Medical Center | 2012-01-01 |
| Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (NCT01491958) | Ohio State University Comprehensive Cancer Center | 2011-12-10 |
| Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (NCT01326845) | Novartis Pharmaceuticals | 2011-12-01 |
| Administration of Donor T Cells With the Caspase-9 Suicide Gene (NCT01494103) | Baylor College of Medicine | 2011-11-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (NCT01240525) | University College, London | 2011-11-01 |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome (NCT01513317) | Janssen Research & Development, LLC | 2011-11-01 |
| VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT01541280) | Nantes University Hospital | 2011-11-01 |
| Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (NCT01295710) | Neovii Biotech | 2011-10-10 |
| Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) (NCT01481220) | Nordic MDS Group | 2011-10-01 |
| Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (NCT01462578) | Technische Universität Dresden | 2011-09-01 |
| Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy (NCT01356875) | Basque Health Service | 2011-09-01 |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) (NCT01385423) | Masonic Cancer Center, University of Minnesota | 2011-09-01 |
| NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases (NCT01370213) | Masonic Cancer Center, University of Minnesota | 2011-09-01 |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (NCT01053806) | Tel-Aviv Sourasky Medical Center | 2011-08-01 |
| Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS) (NCT01305460) | Groupe Francophone des Myelodysplasies | 2011-07-05 |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (NCT01398462) | JW Pharmaceutical | 2011-07-01 |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) (NCT01404741) | Universitätsklinikum Hamburg-Eppendorf | 2011-07-01 |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies (NCT01399840) | Pfizer | 2011-06-30 |
| Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) (NCT01339988) | Tel-Aviv Sourasky Medical Center | 2011-06-01 |
| Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors (NCT01323920) | Dana-Farber Cancer Institute | 2011-05-01 |
| Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (NCT01338987) | National Cancer Institute (NCI) | 2011-04-19 |
| Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients (NCT01152346) | Bioniche Pharma USA LLC | 2011-04-01 |
| Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (NCT00892190) | University of Pittsburgh | 2011-04-01 |
| Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases (NCT01336712) | Northside Hospital, Inc. | 2011-04-01 |
| Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis (NCT01331603) | Wolfson Medical Center | 2011-03-01 |
| MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (NCT01347944) | Celgene | 2011-01-01 |
| Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML (NCT01277484) | Seoul St. Mary's Hospital | 2011-01-01 |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (NCT01451268) | Johann Wolfgang Goethe University Hospital | 2011-01-01 |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (NCT01300611) | Tarix Pharmaceuticals | 2011-01-01 |
| Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea (NCT02137629) | Celgene | 2010-12-27 |
| Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza (NCT01290302) | American Regent, Inc. | 2010-11-22 |
| Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (NCT01196715) | Barts & The London NHS Trust | 2010-11-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (NCT01252784) | Cooperative Study Group A for Hematology | 2010-11-01 |
| Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (NCT01249820) | Radboud University Medical Center | 2010-11-01 |
| PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias (NCT01169012) | UNC Lineberger Comprehensive Cancer Center | 2010-09-01 |
| Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure (NCT01133886) | King's College London | 2010-09-01 |
| Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (NCT01188798) | St. Jude Children's Research Hospital | 2010-09-01 |
| Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (NCT01291745) | Fondazione Amelia Scorza Onlus | 2010-09-01 |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers (NCT01135329) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-08-01 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (NCT01174888) | Alison Walker | 2010-08-01 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |
| Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients (NCT01333449) | Singapore General Hospital | 2010-07-01 |
| Erlotinib in Higher Risk Myelodysplastic Syndrome (NCT01085838) | Groupe Francophone des Myelodysplasies | 2010-07-01 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (NCT01366612) | Hackensack Meridian Health | 2010-06-16 |
| Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (NCT01159028) | Bio-Path Holdings, Inc. | 2010-06-01 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies (NCT01119066) | Memorial Sloan Kettering Cancer Center | 2010-05-03 |